gefitinib has been researched along with vorinostat in 22 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 2,529 | 181 | 1,840 |
Protein | Taxonomy | gefitinib (IC50) | vorinostat (IC50) |
---|---|---|---|
Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
Gli1 | Mus musculus (house mouse) | 2.23 | |
nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
Albumin | Homo sapiens (human) | 0.1072 | |
Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
Histone deacetylase | Zea mays | 0.029 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (4.55) | 29.6817 |
2010's | 18 (81.82) | 24.3611 |
2020's | 3 (13.64) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Li, Y; Lu, SM; Zhang, SQ; Zheng, YW; Zuo, M | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chen, S; Chen, YZ; Ding, C; Hu, G; Jiang, Y; Li, L; Tan, C; Zhang, C; Zhang, W | 1 |
Chu, B; Ding, C; Fan, T; Jiang, Y; Shi, Z; Sun, Q; Tan, C; Yuan, Z; Zhang, C; Zhao, L | 1 |
Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Khochbin, S; Niang, C; Sancey, L | 1 |
Beck, JF; Kurtze, I; Sonnemann, J | 1 |
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M | 1 |
Armini, A; Bianchi, L; Bini, L; Bruzzese, F; Budillon, A; Di Gennaro, E; Gagliardi, A; Gimigliano, A; Leone, A; Pucci, B; Puglia, M; Rocco, M | 1 |
Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S | 1 |
Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T | 1 |
Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Roca, MS; Terranova-Barberio, M; Vitagliano, C | 1 |
Ando, M; Fujiwara, T; Hasegawa, Y; Inoue, A; Katakami, N; Nagase, K; Shimizu, S; Takahashi, T; Takeuchi, S; Yano, S; Yoshimura, K | 1 |
Coll, JL; Couvet, M; Didier, C; Gauche, C; Henry, M; Hurbin, A; Jeannot, V; Josserand, V; Lecommandoux, S; Mazzaferro, S; Schatz, C; Vanwonterghem, L; Vollaire, J | 1 |
Choi, EK; Hwang, JJ; Jeong, SY; Kim, CS; Kim, DE; Kim, MJ; Lee, JS; Park, SE; Rho, JK | 1 |
Bellini, A; Carey, TE; Chiocca, S; Citro, S; Ghiani, L; Miccolo, C | 1 |
Ando, M; Arai, S; Fujiwara, T; Fukuda, K; Hase, T; Hasegawa, Y; Hata, A; Katakami, N; Kawakami, T; Ko, TK; Murakami, H; Nagase, K; Nishiyama, A; Ong, ST; Shimizu, S; Takahashi, T; Takeuchi, S; Tanimoto, A; Yano, S; Yoshimura, K | 1 |
Chen, J; Chen, X; Huang, L; Li, X; Lin, Q; Wong, KC; Xie, W; Zheng, Z | 1 |
2 review(s) available for gefitinib and vorinostat
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
3 trial(s) available for gefitinib and vorinostat
Article | Year |
---|---|
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat | 2015 |
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; Quinazolines; Vorinostat | 2017 |
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Topics: Aged; Aged, 80 and over; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Sequence Deletion; Survival Analysis; Treatment Outcome; Vorinostat | 2020 |
17 other study(ies) available for gefitinib and vorinostat
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Histone Deacetylase Inhibitors; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; Protein Kinase Inhibitors; Salicylamides; Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles | 2017 |
Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Histone Acetyltransferases; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Ku Autoantigen; Lung Neoplasms; Mice; Quinazolines; Subcellular Fractions; Vorinostat | 2010 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat | 2011 |
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Mass Spectrometry; Peptide Mapping; Protein Isoforms; Proteomics; Quinazolines; Software; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Two-Dimensional Difference Gel Electrophoresis; Vorinostat | 2011 |
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Membrane Proteins; Mice; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Voltage-Dependent Anion Channel 1; Vorinostat | 2015 |
Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Female; Gefitinib; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lung Neoplasms; Mice, Nude; Nanoparticles; Vorinostat | 2018 |
Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Reactive Oxygen Species; Vorinostat | 2019 |
Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Gefitinib; Histone Deacetylase Inhibitors; Humans; Papillomaviridae; Papillomavirus Infections; Protein Kinase Inhibitors; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Tumor Suppressor Proteins; Vorinostat | 2019 |
Enabling Single-Cell Drug Response Annotations from Bulk RNA-Seq Using SCAD.
Topics: Gefitinib; RNA-Seq; Sequence Analysis, RNA; Transcriptome; Vorinostat | 2023 |